---
layout: post
title: "Product-Specific Guidance on Estradiol; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:37:02 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-22249
original_published: 2025-12-08 00:00:00 +0000
significance: 8.00
---

# Product-Specific Guidance on Estradiol; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 08, 2025 00:00 UTC
**Document Number:** 2025-22249

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a new draft guidance for industry entitled "Draft Guidance on Estradiol" and a revised draft guidance for industry entitled "Draft Guidance on Estradiol." The new draft guidance and the revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for estradiol vaginal inserts and estradiol vaginal tablets.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/08/2025-22249/product-specific-guidance-on-estradiol-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2025-22249

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
